"Everyone is very excited about the potential of these therapies to treat a variety of diseases. Increasing the access to them will be very important and part of that will be making them the standard of care or frontline therapies. Today, many of them are kind of third to fifth line and we're seeing those move upstream," Motlagh told ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting in San Francisco.

Motlagh argues that to achieve that standard of care the benefit of CGTs must be demonstrated, as well as increasing the access to them across the ecosystem.

Watch the video below to learn more.

CGT ecosystem is only way to accelerate development for more patients: Autolomous COO
Digital solutions provider Autolomous specializes in building solutions for the cell and gene therapy (CGT) industry with an emphasis on collaborative...

Automation, standardization hold potential for overcoming CGT manufacturing challenges
Challenges in cell and gene therapy (CGT) manufacturing can be overcome by fully automating and standardizing the process, contends David Smith, vice...

Galipeau to replace Levine as ISCT president
Dr. Jacques Galipeau, associate dean for therapeutics development at the University of Wisconsin-Madison, is set to replace Bruce Levine, PhD, professor...

ISCT22 co-chair recounts how far CGT industry has come
Advancements in the field of cell and gene therapies (CGTs) have made them a therapeutic reality, according to Bambi Grilley, director of clinical research...

ISCT22: RoosterBio, ShiftBio partner to harness the power of MSCs, exosomes
RoosterBio, a supplier of human mesenchymal stem/stromal cells (MSCs), recently announced a strategic partnership with ShiftBio, a South Korean company...

ISCT22: Scale up of cell therapy manufacturing is a significant, but addressable challenge
The cell therapy industry is facing a significant but addressable challenge when it comes to scaling up manufacturing, according to Bob Newman, PhD, chief...

ISCT22: BroadOak’s Poltilove remains bullish on CGT market despite downturn
Bryan Poltilove, partner at BroadOak Capital Partners, spoke with ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT)...

ISCT22: Orgenesis looks to simplify, lower costs of providing CGT therapies
Personalized cell and gene therapies (CGTs) offer the potential to address the most challenging diseases, Vered Caplan, CEO of biotech company Orgenesis,...

ISCT22: Children's National sees improved cell therapy potency, quicker patient delivery
Children's National Hospital in Washington, DC, is seeing improvements in the potency of existing cell therapies and a reduction in the time it takes...

ISCT22: Antion Biosciences CEO highlights new way of approaching allogeneic cell creation
Dr. Sven Kili, CEO of Antion Biosciences, contends the Swiss company’s microRNA (miRNA) technology (miCAR platform) is a new way of approaching allogeneic...

ISCT president calls for cell and gene therapy education, training amid ‘talent shortage’
This week in San Francisco, industry, investors, physicians, patients, and regulators convened at the International Society for Cell & Gene Therapy (ISCT)...

ISCT working group weighs in on expanded access to CGT
Patricia Zettler, JD, associate professor of law at The Ohio State University, and chair of the International Society for Cell & Gene Therapy (ISCT) Expanded...

ISCT22: Cell therapy has potential to address unmet medical needs in orthopedics
Miguel Forte, CEO of Bone Therapeutics, and president-elect of the International Society for Cell & Gene Therapy (ISCT), spoke with ScienceBoard.net...

ISCT22: Tackling the ethical issues around cell and gene therapy
Unproven and unethical cell and gene therapies are a growing problem worldwide, according to Laertis Ikonomou, PhD, of the Department of Oral Biology...